Objectif Age-related macular degeneration, diabetic retinopathy, and corneal inflammation are significant causes of irreversible blindness with increasing prevalence as the EU population ages and the “diabetes epidemic” expands. There is an unmet clinical need for more effective treatments to halt or reverse these diseases.Many EU pharmaceutical and biotechnology companies, with established processes for the synthesis and physiochemical characterisation of drugs, have bespoke chemical libraries and lead drugs with potential to treat ocular disease, but lack the expertise and infrastructure to test these drugs in relevant pre-clinical models. In parallel, academic labs with excellent infrastructure to study ocular disease, lack the industry expertise to appropriately develop drugs to enter clinical trials. Thus, clinical development of ocular therapeutics is impeded in the EU due to poor collaboration among academic and industry scientists.3D-NET establishes a network of industry (Gadea, KalVista & RenaSci) and academic partners (UCD & UVA), who exchange knowledge and people, and who’s combined S&T expertise will enhance the discovery and development of drugs that target ocular pathologies (retinal vessel permeability, unwanted blood vessel growth, inflammation and cell degeneration). Novel ophthalmic drugs will be discovered from unbiased screens of small molecules and developed from hits/leads and selected compounds (PI3K-inhs, lipoxins, Kallikrein-inhs, HDAC-inhs, serotonin agonists), on a set of in silico/in vitro/in vivo/ex vivo preclinical models.Expected outputs are: a) enhancing intersectoral training, career development and trans-national mobility of EU researchers, b) high impact publications/priority patent applications and c) overcoming barriers that impede industry-academia partnership in the EU inhibiting the discovery/development of new-cheaper and more effective drugs for ocular disease. Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesclinical medicineendocrinologydiabetesmedical and health sciencesbasic medicinepathologymedical and health sciencesclinical medicineophthalmologyretinopathy Programme(s) FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Thème(s) FP7-PEOPLE-2013-IAPP - Marie Curie Action: "Industry-Academia Partnerships and Pathways" Appel à propositions FP7-PEOPLE-2013-IAPP Voir d’autres projets de cet appel Régime de financement MC-IAPP - Industry-Academia Partnerships and Pathways (IAPP) Coordinateur UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN Contribution de l’UE € 717 579,51 Adresse BELFIELD 4 Dublin Irlande Voir sur la carte Région Ireland Eastern and Midland Dublin Type d’activité Higher or Secondary Education Establishments Contact administratif Donal Doolan (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Participants (4) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire UNIVERSIDAD DE VALLADOLID Espagne Contribution de l’UE € 234 967,12 Adresse PLAZA SANTA CRUZ 8 PALACIO DE SANTA CRUZ 47002 VALLADOLID Voir sur la carte Région Centro (ES) Castilla y León Valladolid Type d’activité Higher or Secondary Education Establishments Contact administratif Yolanda Calvo Conde (Ms.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée KALVISTA PHARMACEUTICALS LIMITED Royaume-Uni Contribution de l’UE € 274 693,76 Adresse Phi House, Enterprise road, Southampton Science Park SO16 7NS SOUTHAMPTON Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Robert Haigh (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée GADEA BIOPHARMA SL Espagne Contribution de l’UE € 175 436,17 Adresse Parque Tecnologico de Leon, Edificio Usos 24009 LEON Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Samuel Alonso Martinez (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée RENASCI LIMITED Royaume-Uni Contribution de l’UE € 260 997,44 Adresse PENNYFOOT STREET BIOCITY NOTTINGHAM NG1 1GF NOTTINGHAM Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Rob Jones (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée
